{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:37:16Z","timestamp":1792805836943,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304629"],"award-info":[{"award-number":["82304629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"publisher","award":["3502Z202371048"],"award-info":[{"award-number":["3502Z202371048"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00770-6","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T05:12:32Z","timestamp":1723180352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA\u2019s adverse event reporting system: a case control pharmacovigilance study"],"prefix":"10.1186","volume":"25","author":[{"given":"Wanlong","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-8882","authenticated-orcid":false,"given":"Wei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"issue":"3","key":"770_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA-Cancer J Clin"},{"issue":"3","key":"770_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA-J Am Med Assoc. 2019;321(3):288\u2013300.","journal-title":"JAMA-J Am Med Assoc"},{"issue":"6","key":"770_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2022;20(6):691\u2013722.","journal-title":"J Natl Compr Canc Ne"},{"issue":"3","key":"770_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.clbc.2020.09.010","volume":"21","author":"EA Samuel","year":"2021","unstructured":"Samuel EA, Varella L, Lynn KM, Jia X, Moore H, Thomas BG, Abraham J, Montero AJ. Real-world outcomes of cyclin-dependent kinase inhibitors continued beyond first disease progression in hormone receptor-positive metastatic breast cancer. Clin Breast Cancer. 2021;21(3):205\u20139.","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"770_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/d41573-021-00018-6","volume":"20","author":"P Wilcock","year":"2021","unstructured":"Wilcock P, Webster RM. The breast cancer drug market. Nat Rev Drug Discov. 2021;20(5):339\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"770_CR6","doi-asserted-by":"crossref","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Thromboembolic events with cyclin-dependent kinase 4\/6 inhibitors in the FDA adverse event reporting system. Cancers. 2021;13(8).","DOI":"10.3390\/cancers13081758"},{"issue":"7","key":"770_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","volume":"44","author":"M Silvestri","year":"2021","unstructured":"Silvestri M, Cristaudo A, Morrone A, Messina C, Bennardo L, Nistico SP, Mariano M, Cameli N. Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review. Drug Saf. 2021;44(7):725\u201332.","journal-title":"Drug Saf"},{"issue":"1","key":"770_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","volume":"186","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Tr. 2021;186(1):219\u201327.","journal-title":"Breast Cancer Res Tr"},{"issue":"5","key":"770_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/07357907.2021.1910705","volume":"39","author":"Y Li","year":"2021","unstructured":"Li Y, Li L, Du Q, Li Y, Yang H, Li Q. Efficacy and safety of CDK4\/6 inhibitors combined with endocrine therapy in HR+\/HER-2- ABC patients: a systematic review and meta-analysis. Cancer Invest. 2021;39(5):369\u201378.","journal-title":"Cancer Invest"},{"key":"770_CR10","doi-asserted-by":"crossref","unstructured":"Piezzo M, Chiodini P, Riemma M, Cocco S, Caputo R, Cianniello D, Di Gioia G, Di Lauro V, Rella FD, Fusco G, et al. Progression-free survival and overall survival of CDK 4\/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis. Int J Mol Sci. 2020;21(17).","DOI":"10.3390\/ijms21176400"},{"issue":"10","key":"770_CR11","doi-asserted-by":"publisher","first-page":"e2020312","DOI":"10.1001\/jamanetworkopen.2020.20312","volume":"3","author":"J Li","year":"2020","unstructured":"Li J, Huo X, Zhao F, Ren D, Ahmad R, Yuan X, Du F, Zhao J. Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor-positive metastatic breast cancer: a systematic review and Meta-analysis. JAMA Netw Open. 2020;3(10):e2020312.","journal-title":"JAMA Netw Open"},{"key":"770_CR12","doi-asserted-by":"publisher","first-page":"433558930","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;10:433558930.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"770_CR13","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.jaip.2023.01.027","volume":"11","author":"X Lin","year":"2023","unstructured":"Lin X, Yang J, Weng L, Lin W. Differences in hypersensitivity reactions to iodinated contrast media: analysis of the US food and drug administration adverse event reporting system database. J Aller Cl Imm-Pract. 2023;11(5):1494\u2013502.","journal-title":"J Aller Cl Imm-Pract"},{"issue":"9","key":"770_CR14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","volume":"44","author":"A Mascolo","year":"2021","unstructured":"Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del RM, Russo A, Coscioni E, Rossi F, Alfano R, et al. Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in Eudravigilance. Drug Saf. 2021;44(9):957\u201371.","journal-title":"Drug Saf"},{"key":"770_CR15","unstructured":"FDA. FDA Adverse Event Reporting System Public Dashboard. 2023."},{"issue":"7","key":"770_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"3","key":"770_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","volume":"26","author":"EG Brown","year":"2003","unstructured":"Brown EG. Methods and pitfalls in searching drug safety databases utilising the medical dictionary for regulatory activities (MedDRA). Drug Saf. 2003;26(3):145\u201358.","journal-title":"Drug Saf"},{"issue":"2","key":"770_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"HJ Duggirala","year":"2016","unstructured":"Duggirala HJ, Tonning JM, Smith E, Bright RA, Baker JD, Ball R, Bell C, Bright-Ponte SJ, Botsis T, Bouri K, et al. Use of data mining at the food and drug administration. J Am Med Inf Assn. 2016;23(2):428\u201334.","journal-title":"J Am Med Inf Assn"},{"key":"770_CR19","doi-asserted-by":"crossref","unstructured":"Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021;22(6).","DOI":"10.1093\/bib\/bbab347"},{"key":"770_CR20","doi-asserted-by":"crossref","unstructured":"Pace ND, Multani JK. On the reporting of odds ratios and risk ratios. Nutrients. 2018;10(10).","DOI":"10.3390\/nu10101512"},{"key":"770_CR21","unstructured":"FDA. IBRANCE\u00ae (palbociclib) capsules label. Revised Apr 2019."},{"key":"770_CR22","unstructured":"FDA. KISQALI\u00ae (ribociclib) tablets label. Revised Oct 2022."},{"key":"770_CR23","unstructured":"FDA. VERZENIO\u00ae (abemaciclib) tablets label. Revised Oct 2021."},{"issue":"3","key":"770_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","volume":"21","author":"CE Onesti","year":"2021","unstructured":"Onesti CE, Jerusalem G. CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticanc. 2021;21(3):283\u201398.","journal-title":"Expert Rev Anticanc"},{"issue":"2","key":"770_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"770_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.stem.2015.01.017","volume":"16","author":"E Laurenti","year":"2015","unstructured":"Laurenti E, Frelin C, Xie S, Ferrari R, Dunant CF, Zandi S, Neumann A, Plumb I, Doulatov S, Chen J, et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell. 2015;16(3):302\u201313.","journal-title":"Cell Stem Cell"},{"issue":"10","key":"770_CR27","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","volume":"15","author":"P Chen","year":"2016","unstructured":"Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther. 2016;15(10):2273\u201381.","journal-title":"Mol Cancer Ther"},{"issue":"10226","key":"770_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817\u201327.","journal-title":"Lancet"},{"issue":"2","key":"770_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-18-0734","volume":"18","author":"S Thibault","year":"2019","unstructured":"Thibault S, Hu W, Hirakawa B, Kalabat D, Franks T, Sung T, Khoh-Reiter S, Lu S, Finkelstein M, Jessen B, et al. Intestinal toxicity in rats following administration of CDK4\/6 inhibitors is independent of primary pharmacology. Mol Cancer Ther. 2019;18(2):257\u201366.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"770_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1188\/12.CJON.413-417","volume":"16","author":"C Shaw","year":"2012","unstructured":"Shaw C, Taylor L. Treatment-related diarrhea in patients with cancer. Clin J Oncol Nurs. 2012;16(4):413\u20137.","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"770_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000499534","volume":"14","author":"J Ettl","year":"2019","unstructured":"Ettl J. Management of adverse events due to cyclin-dependent kinase 4\/6 inhibitors. Breast Care. 2019;14(2):86\u201392.","journal-title":"Breast Care"},{"issue":"6","key":"770_CR32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. New Engl J Med. 2020;382(6):514\u201324.","journal-title":"New Engl J Med"},{"issue":"24","key":"770_CR33","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465\u201372.","journal-title":"J Clin Oncol"},{"issue":"1","key":"770_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"S Johnston","year":"2023","unstructured":"Johnston S, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390.","journal-title":"Lancet Oncol"},{"issue":"2","key":"770_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jcph.792","volume":"57","author":"Y Yu","year":"2017","unstructured":"Yu Y, Loi CM, Hoffman J, Wang D. Physiologically based pharmacokinetic modeling of palbociclib. J Clin Pharmacol. 2017;57(2):173\u201384.","journal-title":"J Clin Pharmacol"},{"key":"770_CR36","doi-asserted-by":"crossref","unstructured":"Gao S, Li Y, He Z, Zhu J, Liang D, Yang S, Mo J, Lam K, Yu X, Huang M, et al. Thromboembolism profiles associated with cyclin-dependent kinase 4\/6 inhibitors: a real-world pharmacovigilance study and a systematic review. Expert Opin Drug Saf. 2023:1\u201311.","DOI":"10.1080\/14740338.2023.2181338"},{"key":"770_CR37","doi-asserted-by":"crossref","unstructured":"Master SR. Cardiac complications of CDK4\/6 inhibitors for breast cancer. In: 2020 ASCO annual meeting. 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.e13038"},{"issue":"1","key":"770_CR38","doi-asserted-by":"publisher","first-page":"e1402","DOI":"10.1002\/cnr2.1402","volume":"5","author":"H Nawa","year":"2022","unstructured":"Nawa H, Niimura T, Yagi K, Goda M, Zamami Y, Ishizawa K. Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments. Cancer Rep-US. 2022;5(1):e1402.","journal-title":"Cancer Rep-US"},{"issue":"131","key":"770_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1183\/09059180.00009113","volume":"23","author":"KM Antoniou","year":"2014","unstructured":"Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respir Rev. 2014;23(131):40\u201354.","journal-title":"EUR RESPIR REV"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00770-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T17:04:29Z","timestamp":1723223069000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00770-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study was used a public, de-identified database of spontaneous reports. This study was deemed non\u2011human subject related research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}